1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AACR Round-Up: BMS, Lilly, iTeos, Affimed, Treovir, Revolution And Cardiff

Immuno-Oncology Highlights Include TIGIT, NK Cell Booster & HSV Oncolytic

 
• By Mandy Jackson and Joseph Haas

iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.

Cancer cell 3D
Immunotherapy boosters, an oncolytic HSV therapy and other novel therapies were presented at AACR • Source: Shutterstock

Elaborating on top-line data it announced last October, Bristol Myers Squibb Company reported on 10 April that Opdivo can yield pathologic complete response in pre-surgical non-small cell lung cancer patients, the first time an immunotherapy has demonstrated pathological response in a Phase III study in neoadjuvant lung cancer.

The pharma outlined the early data from its CheckMate-816 trial in October saying Opdivo (nivolumab) plus chemotherapy bested chemotherapy alone on pCR in patients with resectable stage Ib to IIIa NSCLC. (Also see "Bristol Claims A First With Opdivo In Neoadjuvant NSCLC" - Scrip, 7 October, 2020

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.